Pfizer, BioNTech's Coronavirus Vaccine Possibly Ready for Approval by End-Of-Year
Pfizer Inc and BioNTech's COVID-19 coronavirus vaccine candidate might be ready to begin seeking full regulatory approval by the end of 2020, according to an exclusive report from The Wall Street Journal on Friday, quoting the chief executive officer of the biotech company.
Coronavirus vaccine candidate to seek approval before 2021
This experimental vaccine showed promise as a viable candidate to slow and possibly reverse the advance of the rapid advancing respiratory illness. At the moment it's still in early-stage human testing, but it's expected to enter a large trial, with 30,000 healthy participants later July 2020, pending permission from regulatory authorities.
UPDATE July 7, 3:22 PM EDT: Pfizer, BioNTech prepare to make 100 million doses
If both companies receive approval to move their marketing phase forward, a report from Reuters says they're prepared to mass-produce 100 million doses of the coronavirus vaccine candidate before the end of 2020, with an additional 1.2 billion doses ready before the end of 2021 from sites in the U.S. and Germany.
The initial report from the WSJ also said several hundred million doses might even be produced by the pharmaceutical companies before they receive marketing approval. While it's too soon to know whether we'll see the vaccine candidate come to fruition, Pfizer's early production would rapidly shorten the timetable for dispersing a vaccine that could prove to be a critical blow against the world-historic coronavirus crisis.
A new study joins the body of research showing that being bilingual, knowing more than one language, slows down the negative effects of aging on the brain.